[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"cognitive-dysfunction-cognitive-disorder\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:cognitive-dysfunction-cognitive-disorder":33},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,51,102],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":34,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":40,"lastUpdatePostDateStruct":41,"startDateStruct":44,"completionDateStruct":46,"leadSponsor":48,"locationsCount":4},"100641553","cognitive-based-balance-rehabilitation-in-parkinsons-disease-virtual-reality-vs-dual-task-100641553",false,"NCT07660978","Cognitive-Based Balance Rehabilitation in Parkinson's Disease: Virtual Reality vs. Dual Task","Effects of Cognitive-Based Balance Rehabilitation on Balance, Gait and Cognitive Functions in Parkinson's Disease Patients: Comparison of Virtual Reality and Dual Task","Inclusion Criteria:\n\n* Diagnosed with Parkinson's Disease by a neurologist.\n* Hoehn \\& Yahr Stage I-III.\n* Aged between 40-80 years.\n* Literate and capable of performing basic mathematical calculations.\n* Montreal Cognitive Assessment≥21\n* Stable pharmacological treatment.\n* Physician's approval for exercise participation.\n\nExclusion Criteria:\n\n* Currently participating in another exercise or drug trial.\n* Presence of any additional neurological disorders.\n* Significant musculoskeletal disorders, arthritis, or cardiovascular disease.\n* Uncontrolled epilepsy or severe orthostatic hypotension.\n* Engaged in regular moderate-intensity exercise more than once a week in the last 6 months.","ALL","40 Years","80 Years",{"count":20,"type":21},34,"ESTIMATED","INTERVENTIONAL",[24],"NA","This prospective, randomized, single-blind, controlled clinical trial aims to evaluate and compare the efficacy of cognitive-based balance rehabilitation delivered via immersive Virtual Reality (VR) versus traditional Dual-Task Training (DTT) on balance, gait, cognitive functions, and quality of life in patients with Parkinson's Disease (PD). Postural instability and cognitive decline are hallmark features of progressive PD that significantly elevate fall risks and compromise daily independence, yet conventional pharmacological therapies offer limited effectiveness in restoring complex postural control. Given that motor and cognitive processes are intrinsically linked, this study addresses a critical gap in neurorehabilitation by investigating two contemporary modalities designed to challenge these systems simultaneously. A total of 34 participants diagnosed with PD (aged 40-80 years, Hoehn and Yahr stages I-III) will be randomly allocated to either the Dual-Task Group (DTG), receiving structured therapeutic exercises integrated with sequential cognitive tasks, or the Virtual Reality Group (VRG), engaging in an immersive balance program utilizing the Oculus Quest 2® headset with the FIT-XR application. Both groups will undergo an identical intervention protocol consisting of 45-minute supervised sessions, conducted twice weekly for 8 consecutive weeks during their pharmacological \"on\" phase. Standardized assessments will be performed by a blinded clinician at baseline and post-intervention (Week 8). The primary outcome measures will be dynamic balance and gait assessed through the Mini-Balance Evaluations Systems Test (Mini-BESTest) alongside global cognitive performance measured via the Montreal Cognitive Assessment (MoCA). Secondary outcomes will encompass objective posturographic indices using the Biodex Balance System, motor severity via the Unified Parkinson's Disease Rating Scale (UPDRS-III), freezing of gait, health-related quality of life, global perceived improvement, and potential cyber-sickness symptoms monitored through the Virtual Reality Sickness Questionnaire (VRSQ) to comprehensively determine the safety and comparative therapeutic value of these interventions.",[27,28,29,30,31,32,33],"PARKINSON DISEASE (Disorder)","Parkinson Disease (PD)","Parkinson s Disease","Postural Instability","Postural Instability Gait Disorders","Gait Disorders","Cognitive Dysfunction, Cognitive Disorder",[35,30,32,36,37,38],"Parkinson Disease","Cognitive Dysfunction","Dual Task","Virtual Reality","NOT_YET_RECRUITING","2026-06-23",{"date":42,"type":43},"2026-06-25","ACTUAL",{"date":45,"type":21},"2026-06-20",{"date":47,"type":21},"2027-12-30",{"name":49,"class":50},"Bezmialem Vakif University","OTHER",{"id":52,"slug":53,"hasResults":11,"nctId":54,"briefTitle":55,"officialTitle":55,"acronym":56,"eligibilityCriteria":57,"healthyVolunteers":58,"sex":16,"minAge":59,"maxAge":60,"enrollmentInfo":61,"targetDuration":4,"studyType":63,"phases":4,"briefSummary":64,"conditions":65,"keywords":69,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":92,"lastUpdatePostDateStruct":93,"startDateStruct":95,"completionDateStruct":97,"leadSponsor":99,"locationsCount":101},"100633056","div-ad-barcelona-alzheimers-blood-based-biomakers-for-a-diverse-community-100633056","NCT07521722","DIV-AD BARCELONA: Alzheimer's Blood-Based Biomakers for a Diverse Community","DIV-AD","INCLUSION CRITERIA\n\n* Cognitively Unimpaired individuals aged between 50 and 75 years at the time of signing the informed consent\n* Individuals interested in participating, able to follow study procedures, and who understand that all the tests are carried out in a research context.\n* Explicit desire to participate in the tests and procedures of the study, including: collection of study variables, cognitive and neurologic assessment, blood sampling.\n* Signing the informed consent, agreeing not to receive the research results that will not be of no clinical interest for the participant.\n\nEXCLUSION CRITERIA\n\n* Cognitive decline defined by CDR\\>0.\n* Individuals with cognitive complaints and who have sought for medical help for cognitive impairment at any time in their life\n* Patients with relevant medical illnesses that may significantly interfere with the interpretation of results. This includes auditory and visual perception disorders, active oncological disease under treatment (localized tumors are excluded) and any condition that, in the investigator's opinion, may interfere with the correct performance\u002Finterpretation of the study procedures and\u002For with future permanence in the study.\n* Major psychiatric disorders (according to the DSM-V manual) or diseases that affect cognitive abilities (major depressive episode, bipolar disorder, schizophrenia, etc).\n* Acquired brain damage: history of head trauma with macroscopic parenchymal or non-axial lesion, large-vessel ischemic or hemorrhagic stroke, brain tumours and any other etiologies that can cause acquired brain damage (i.e., chemotherapy or brain radiotherapy).\n* Parkinson's disease, epilepsy under treatment and with frequent seizures (\\> 1\u002Fmonth) in the last year, multiple sclerosis or other neurodegenerative diseases.",true,"50 Years","75 Years",{"count":62,"type":21},250,"OBSERVATIONAL","The DIV-AD study aims to find out whether levels of Alzheimer's disease markers in blood differ among the main ethnical groups living in central Barcelona.\n\nIt will also examine how factors such as age, income, education, and health conditions may affect these levels.\n\nIn addition, the study will identify barriers that may make it difficult to use these blood tests in primary care.\n\nThe final goal is to help ensure that everyone in Barcelona has fair access to early prevention strategies for Alzheimer's disease.",[66,33,67,68],"Alzheimer Disease","Dementia","Neurodegenerative Disease",[70,71,72,73,74,75,76,77,78,79,80,81,82,83,84,85,86,87,88,89,90,91],"Alzheimer's disease","AD","Blood-based biomarkers","Plasma biomarkers","Phosphorylated tau","Amyloid beta","Neurofilament light chain","GFAP","Ethnic diversity","Health disparities","Cognitively unimpaired","Preclinical Alzheimer's disease","Primary care","Dementia prevention","Cross-cultural cognitive assessment","RUDAS","Dementia knowledge","Dementia stigma","Genetic ancestry","Migrant populations","Health equity","Diversity","2026-04-07",{"date":94,"type":43},"2026-04-13",{"date":96,"type":21},"2026-04-27",{"date":98,"type":21},"2029-01-01",{"name":100,"class":50},"Barcelonabeta Brain Research Center, Pasqual Maragall Foundation",1,{"id":103,"slug":104,"hasResults":11,"nctId":105,"briefTitle":106,"officialTitle":106,"acronym":4,"eligibilityCriteria":107,"healthyVolunteers":58,"sex":16,"minAge":108,"maxAge":60,"enrollmentInfo":109,"targetDuration":4,"studyType":22,"phases":111,"briefSummary":112,"conditions":113,"keywords":4,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":116,"lastUpdatePostDateStruct":117,"startDateStruct":119,"completionDateStruct":121,"leadSponsor":123,"locationsCount":4},"100601725","a-pet-and-tau-pet-imaging-in-the-diagnosis-and-progression-assessment-of-alzheimers-disease-100601725","NCT07114224","Aβ PET and Tau PET Imaging in the Diagnosis and Progression Assessment of Alzheimer's Disease","Inclusion Criteria:\n\n* Age: 18-75 years old; Healthy volunteers: males weighing ≥50 kg, females weighing ≥45 kg, with a body mass index (BMI = weight (kg)\u002Fheight² (m²)) within the range of 19.0-28.0 kg\u002Fm² (including boundary values); Cognitive disorders diagnosed clinically according to guidelines include Alzheimer's disease (AD) and mild cognitive impairment (MCI). Diagnostic criteria are as follows: 1) Clinical manifestations include symptoms such as memory impairment, difficulty concentrating, slowed thinking, and poor language skills; 2) Neuropsychological tests show that functions such as memory, attention, thinking, and language are below the normal population level; 3) Blood or cerebrospinal fluid tests show elevated levels of human β-amyloid 1-42, human β-amyloid 1-40, and human phosphorylated tau protein. 4) Exclusion of other factors that may cause cognitive impairment, such as drug or substance abuse, environmental factors, etc.; Signing an informed consent form for PET\u002FMR or PET\u002FCT examinations and voluntarily participating in this study.\n\nExclusion Criteria:\n\n* Minors, pregnant women, breastfeeding women, individuals with severe liver or kidney dysfunction, and those with a history of allergy to contrast agents or other medications; Diagnosed with viral encephalitis, acute myelitis, idiopathic epilepsy, or antibody-negative AIE; Diagnosed with any major illness; history of alcohol or drug abuse\u002Fdependence; History of cardiovascular disease, tumours, blood disorders, or poorly controlled chronic conditions; Contraindications for PET\u002FMR imaging. History of head trauma or surgery; History of other neurological disorders.","18 Years",{"count":110,"type":21},70,[24],"This prospective study recruited 20 healthy volunteers and 50 patients diagnosed with Alzheimer's disease (AD) and mild cognitive impairment (MCI) according to clinical guidelines. Participants underwent AV45\u002FAV-1 and AV1451 PET imaging to obtain information on Aβ protein deposition, tau protein distribution, and structural and functional information. The study aims to evaluate the value of multimodal imaging features in the diagnosis and progression assessment of AD, providing imaging evidence for novel treatment modalities such as lecanemab therapy and deep cervical vein-lymphatic anastomosis.",[114,33,115],"Alzheimer Disease (AD)","PET Imaging","2025-08-04",{"date":118,"type":43},"2025-08-11",{"date":120,"type":21},"2025-08-15",{"date":122,"type":21},"2027-06-01",{"name":124,"class":50},"Xijing Hospital"]